The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.

07:00 EST 12th February 2019 | BioPortfolio

Summary of "The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer."

We retrospectively investigated the genomic prostate score assay in clinical practice at an urban tertiary care academic center.


Journal Details

This article was published in the following journal.

Name: The Journal of urology
ISSN: 1527-3792
Pages: 101097JU0000000000000170


DeepDyve research library

PubMed Articles [25905 Associated PubMed Articles listed on BioPortfolio]

Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than PI-RADS Score in Multi-Parametric Prostate MRI-Ultrasound Fusion Targeted Biopsies.

To assess the association between Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score, the Decipher score and histologic grade of carcinoma in biopsy tissue among low- to intermedia...

A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.

To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) biopsy-based gene expression assay as a predictor of adverse pathology (AP, Gleason score [pGS] ≥ 4+3 and/or ≥ pT3) in a prospectiv...


Genomic testing may improve risk stratification for men with prostate cancer managed with active surveillance (AS). We aimed to characterize the stability and utility of serial genomic test scores in ...

Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.

To determine the cost-effectiveness of using the Oncotype DX Genomic Prostate Score (GPS), a 17-gene expression assay that can be used to inform decisions regarding active surveillance (AS) versus imm...

Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer.

The majority of clinical prostate cancers are multifocal with morphological and molecular heterogeneity. Adequate tissue representation is crucial for the clinical utility of multigene panel sequencin...

Clinical Trials [7849 Associated Clinical Trials listed on BioPortfolio]

LDR Brachytherapy Versus SBRT for Low and Intermediate Risk Prostate Cancer Patients

The aim of this trial is to find out if there are any differences in the profiles of acute and late adverse effects among men with low and intermediate risk prostate cancer treated either ...

Registry to Measure the Impact of Adding Genomic Testing

This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage local...

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-Africa...

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evalu...

Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer

In this study we aim to more precisely define the clinical utility of PSMA imaging across a range of clinical indications in men with prostate cancer. To accomplish this, we will make the ...

Medical and Biotech [MESH] Definitions

A method, developed by Dr. Virginia Apgar, to evaluate a newborn's adjustment to extrauterine life. Five items - heart rate, respiratory effort, muscle tone, reflex irritability, and color - are evaluated 60 seconds after birth and again five minutes later on a scale from 0-2, 0 being the lowest, 2 being normal. The five numbers are added for the Apgar score. A score of 0-3 represents severe distress, 4-7 indicates moderate distress, and a score of 7-10 predicts an absence of difficulty in adjusting to extrauterine life.

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

An anatomic severity scale based on the Abbreviated Injury Scale (AIS) and developed specifically to score multiple traumatic injuries. It has been used as a predictor of mortality.

Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.

Quick Search


DeepDyve research library

Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Searches Linking to this Article